

RESPIMAT® T.O.P. PERFORMER
CHALLENGE



Are you a T.O.P. Performer?
Take our quiz
and find out!

Play now!

Pharmacy
Times

PC-01311 12/16

PHARMACY INFORMATION FOR TODAY'S PHARMACIST
**Pharmacy
Times**

Sign up for the [PharmacyTimes Newsletter](#)

SHOWING CONTENT FOR:
Community Pharmacist

Login

Clinical
Resources

Videos

Publications

Contributors

Conference
Coverage

Continuing
Education

Search

Back to issue

Apotex

AUGUST 24, 2016

APOTEX
ADVANCING GENERICS

APOTEX
ADVANCING GENERICS

Apotex Corp., headquartered in Weston, Florida, is the U.S. affiliate of Apotex Inc., the 7th largest generic pharmaceutical company in the world. Apotex employs over 10,000 people and can produce up to 24 billion dosages a year across a full range of dosage forms, including tablets, capsules, oral suspensions, ophthalmic, nasals and liquid products. These products are sold into more than 120 countries around the world. A strong pipeline of over 300 more products in development is the key to keeping this strong market presence.

Frequently recognized for superior service by customers, Apotex Corp. is ranked in the top ten U.S. generic pharmaceutical manufacturers by sales and is 10th in total generic prescriptions, according to recent IMS HEALTH data. Apotex's expansive product portfolio spans a wide range of therapeutic classes, including cardiovascular, anti-infectives, gastrointestinal, central nervous system, mental health, pain management and respiratory. The company continues to diversify its product mix by adding new therapeutic areas and dosage forms such as transdermal patches and injectables. Recently, Apotex launched the first generic version of Merck's Nasonex® nasal spray (mometasone furoate monohydrate) in the United States.

"We are very pleased to make a more affordable version of this important allergy medicine available to the U.S. public. Apotex is dedicated to bringing high quality versions of complex generic products to market, and we are delighted that these efforts will generate substantial savings for the U.S. healthcare system," said Apotex Chief Executive Officer and President, Dr. Jeremy B. Desai.

Apotex has long been known for building strong industry partnerships to champion the cause of making affordable medicines and driving down healthcare costs. One such partnership is with the Generic Pharmaceutical Association (GPhA). In February of this year, Jeff Watson, President, Global Generics was appointed to the 2016 GPhA Board of Directors. "This industry continues to be the most reliable source of savings in the health sector," said Watson. "I look forward to working with the association leadership to advance the mission of GPhA and its member companies, improving the lives of millions of patients while enhancing timely access to quality, affordable medicines."

A Forward-Thinking Approach

Apotex is passionate in its approach to research and development. The company will spend \$2 billion in the next ten years on R&D, with a significant portion of those resources focused on the company's emerging biosimilar program. Apotex currently has two biosimilar applications (filgrastim [Neupogen®] and pegfilgrastim [Neulasta®]) under active review with the FDA. "We are very pleased to be at the forefront of companies who will introduce high quality biosimilar products into the U.S. marketplace," said Dr. Desai. "Our entry into this new frontier of medicine is a watershed event in Apotex's 42-year history."

We want to know your top recommended OTC products!

Pharmacy Times® and U.S. News would like to hear what OTC products you most often recommend. You will have the chance to win an iPhone X!

Pharmacist Education

Clinical features with downloadable PDFs

Apotex believes all manufacturers have a corporate citizenship responsibility to the global community. The company carries out this responsibility through various national initiatives and partnerships and continues to donate life-saving medicines to developing countries to alleviate human suffering and save the lives of many people around the world. Apotex is committed to serving patients by advancing generics and providing high quality, affordable products.

For more information, visit www.apotexcorp.com.

SHARE THIS



RELATED COVERAGE



FDA Approves Generic Drug for Relapsing Multiple Sclerosis



Generic Product News (January 2018)



Clinical Use of Generic Injectable Drugs in Hospitalized Patients

YOU MAY ALSO BE INTERESTED IN



Top 200 Drugs of 2010

SIGN UP FOR THE PHARMACY TIMES NEWSLETTER

Personalize the information you receive by selecting targeted content and special offers.

Enter your email address [Sign Up]

Savings Streamlined. Bring value to your patients by using Cou-Co.com to save them time and money. [Image of pharmacy staff]

RELATED SITES



About Pharmacy Times

Pharmacy Times® is the #1 full-service pharmacy media resource in the industry. Founded in 1897, Pharmacy Times® reaches a network of over 1.3 million retail pharmacists. Through our print, digital and live events channels, Pharmacy Times® provides clinically based, practical and timely information for the practicing pharmacist. Features and specialized departments cover medication errors, drug interactions, patient education, pharmacy technology, disease state management, patient counseling, product news, pharmacy law and health-system pharmacy. Pharmacy Times Continuing Education™ (PTCE) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing



Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-9038

[Careers](#) [Contact Us](#) [Feedback](#) [Advertise With Us](#) [Terms & Conditions](#) [Privacy](#) [Press Room](#) [Conference Coverage](#)

Copyright © 2006-2017 Pharmacy & Healthcare Communications, LLC. All Rights Reserved.

